Singulair Advantage In Allergies Is Leukotriene-Blocking Action, Merck Says
Executive Summary
Merck's Singulair AR novel mechanism of action allows the asthma drug to work across multiple allergic rhinitis symptoms, Human Health President-Americas David Anstice told investors
You may also be interested in...
Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies
Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions
Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies
Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions
Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says
Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call